Author:
West Erin A., ,Anker Daniela,Amati Rebecca,Richard Aude,Wisniak Ania,Butty Audrey,Albanese Emiliano,Bochud Murielle,Chiolero Arnaud,Crivelli Luca,Cullati Stéphane,d’Acremont Valérie,Epure Adina Mihaela,Fehr Jan,Flahault Antoine,Fornerod Luc,Frank Irène,Frei Anja,Michel Gisela,Gonseth Semira,Guessous Idris,Imboden Medea,Kahlert Christian R.,Kaufmann Laurent,Kohler Philipp,Mösli Nicolai,Paris Daniel,Probst-Hensch Nicole,Rodondi Nicolas,Stringhini Silvia,Vermes Thomas,Vollrath Fabian,Puhan Milo A.
Abstract
Abstract
Objectives
Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community.
Methods
Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-stratified, with some regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also planned. The studies will assess population immunological status during the pandemic.
Results
Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8% (95% CI 8.2–13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg recruited a total of 5973 participants for phase two thus far.
Conclusions
Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in both economic and societal sectors.
ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health (social science)
Reference28 articles.
1. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E et al (2020) (2020) SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis 3099(20):9–10. https://doi.org/10.1016/S1473-3099(20)30631-9
2. Bobrovitz N, Arora RK, Yan T, Rahim H, Duarte N, Boucher E et al (2020) Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys. medRxiv. https://doi.org/10.1101/2020.05.10.20097451
3. Corona Immunitas (2020) Choosing a common test. https://www.de.corona-immunitas.ch/blog/choosing-a-common-test. Accessed 21 July 2020
4. de Mestral C, Stringhini S, Guessous I, Jornayvaz FR (2019) Thirteen-year trends in the prevalence of diabetes in an urban region of Switzerland: a population-based study. Diabet Med 2019:1374–1378
5. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S et al (2020) (2020) Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 6:CD013652